-
Ibrexafungerp: Reading Resistance Data Correctly
2026-09-16
Ibrexafungerp and MK 3118 offer a powerful way to study glucan-synthase inhibition beyond conventional echinocandin assumptions. This article explains how genotype, assay standardization, acidic-pH biology, and infection models should be integrated when interpreting resistance data.
-
Sulfachloropyridazine: Applied DHPS Workflows
2026-09-15
Sulfachloropyridazine connects mechanism-focused DHPS inhibition with antimicrobial susceptibility testing, microbiome profiling, and infection-model research. This guide shows how to build solvent-controlled assays, interpret microbiota and metabolomics data, and troubleshoot common formulation and translation problems.
-
DMXAA (Vadimezan) Assay Workflows
2026-09-15
Build reproducible DMXAA experiments around tumor vascular disruption, endothelial apoptosis, VEGFR2 signaling, and A549 cell responses. This practical guide pairs concentration-control strategies with imaging and pathway readouts, while showing how a COPII–STING trafficking study can inspire better assay design without overstating cross-domain evidence.
-
IR-820: From NIR Imaging to Translational Insight
2026-09-14
IR-820, also known as New Indocyanine Green, is more than a near-infrared imaging reagent: it can serve as a strategic bridge between biodistribution, vascular mapping, tumor visualization, and therapy-oriented study design. This thought-leadership article examines how its optical behavior can inform translational workflows while distinguishing product-specific evidence from findings generated with ICG-loaded nanomedicines.
-
Separating Cytostasis from Cell Death in Cancer Drug Testing
2026-09-14
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that cancer drugs can suppress proliferation and induce cell death in different proportions and on different timelines. This framework improves interpretation of in vitro drug-response experiments, including studies of histone deacetylase inhibition where cell-cycle arrest may otherwise be mistaken for cytotoxicity.
-
NHS-Biotin for Multimeric Protein Assays
2026-09-13
NHS-Biotin provides a compact, irreversible tag for antibody, nanobody, and protein workflows, from streptavidin detection to affinity purification. Its membrane permeability and short spacer arm also support intracellular labeling and quality control of engineered multimeric assemblies.
-
Super-enhancer–FOXA1–SLC7A11 Axis in Prostate Cancer
2026-09-12
This study identifies a super-enhancer–FOXA1–SLC7A11 regulatory axis that links prostate cancer transcriptional control with disulfidptosis, a metabolic form of cell death triggered by cystine stress during glucose deprivation. Its combination of computational analysis, engineered cell models, chromatin profiling, reporter assays, and CRISPR-Cas9 enhancer deletion provides a framework for testing how tumor-specific regulatory elements shape metabolic vulnerability.
-
Luminescent ATP Detection Assay Kit in NSCLC
2026-09-12
Discover how the Luminescent ATP Detection Assay Kit converts ATP abundance into a mechanistic readout of pyruvate carboxylase–regulated ferroptosis in NSCLC. This guide connects firefly luciferase ATP assay design with cellular and tissue workflows, normalization strategies, and interpretation limits.
-
Metronidazole: A Translational View of OAT3
2026-09-11
Metronidazole is more than a familiar nitroimidazole antibiotic: its defined OAT3 inhibition creates a practical bridge between antimicrobial perturbation, transporter biology, and drug-drug interaction research. This thought-leadership guide shows how translational teams can separate these effects, validate them experimentally, and use the compound strategically rather than treating it as a conventional product-page reagent.
-
VE-821: From ATR Checkpoints to Epigenetic Assays
2026-09-11
VE-821 is a selective ATR kinase inhibitor for dissecting checkpoint failure, radiosensitization, and chemotherapy sensitization. This article connects ATR–Chk1 signaling with DNMT1-dependent viral DNA regulation while clearly separating established evidence from testable cross-domain hypotheses.
-
Phosbind Acrylamide for Plant MAPK Analysis
2026-09-10
Phosbind Acrylamide enables antibody-free protein phosphorylation analysis by resolving phosphorylation-dependent mobility changes in SDS-PAGE. This article connects its assay logic to a 2025 peach immunity study and explains how to distinguish pathway mechanism, kinase activity, and gel-based evidence.
-
GSK-923295 Workflows for CENP-E Mitosis Studies
2026-09-10
GSK-923295 enables controlled CENP-E inhibition for studying chromosome alignment, mitotic arrest, and cancer-cell vulnerability. This practical guide connects biochemical potency with imaging, viability, and centromere-focused workflows while separating direct CENP-E phenotypes from broader centromere defects.
-
Ranolazine Beyond Ischemia: A Translational Framework
2026-09-09
Ranolazine is more than a late sodium current inhibitor: it is a mechanistically useful probe of ion handling, myocardial relaxation, and metabolic substrate selection. This thought-leadership framework connects cardiac ischemia research with liver metabolism while clearly separating established evidence from exploratory applications inspired by recent HBV biology.
-
Clodronate Liposomes for Liver I/R Research
2026-09-09
Clodronate Liposomes provide a practical way to test whether macrophages are causal drivers of hepatic ischemia-reperfusion injury rather than merely associated with it. This workflow combines controlled depletion, PBS-liposome controls, tissue verification, and single-cell-informed readouts for more defensible immune cell modulation studies.
-
AS1842856: A Foxo1 Assay Decision Guide
2026-09-08
AS1842856 is a Foxo1 inhibitor for separating direct transcription-factor control from upstream PI3K-Akt signaling. This guide connects gluconeogenesis, autophagy research, and MSC assays while emphasizing controls, readouts, and translational limits.